Halozyme announces Roche receives EC marketing authorization of Tecentriq SC

Halozyme (HALO) announced that Roche (RHHBY) received European Commission, or EC, marketing authorization of Tecentriq SC co-formulated with Enhanze, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20. The approval applies to all approved indications of Tecentriq IV and represents the European Union’s first PD-(L)1 cancer immunotherapy for subcutaneous injection.